A phase III trial of evogliptin for type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2015
At a glance
- Drugs Evogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 09 Oct 2015 New trial record
- 02 Oct 2015 According to a Dong-A St media release, the South Korean MFDS (Ministry of Food and Drug Safety) has approved the NDA of SUGANON (DA-1229, Evogliptin 5mg tablet) for type 2 diabetes mellitus.
- 31 Dec 2014 According to the company Annual Report 2014, a New Drug Application was filed in 2015 for evogliptin to the South Korean MFDS (Ministry of Food and Drug Safety).